• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

抗微生物药物使用与耐大环内酯肺炎链球菌，比利时。

Antimicrobial drug use and macrolide-resistant Streptococcus pyogenes, Belgium.

机构信息

University of Antwerp, Antwerp, Belgium.

出版信息

Emerg Infect Dis. 2012 Sep;18(9):1515-8. doi: 10.3201/eid1809.120049.

DOI:10.3201/eid1809.120049
PMID:22932671
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3437719/
Abstract

In Belgium, decreasing macrolide, lincosamide, streptogramins B, and tetracycline use during 1997-2007 correlated significantly with decreasing macrolide-resistant Streptococcus pyogenes during 1999-2009. Maintaining drug use below a critical threshold corresponded with low-level macrolide-resistant S. pyogenes and an increased number of erm(A)-harboring emm77 S. pyogenes with low fitness costs.

摘要

在比利时，1997 年至 2007 年间大环内酯类、林可酰胺类、链阳菌素 B 和四环素类药物的使用减少，与 1999 年至 2009 年间耐大环内酯类肺炎链球菌的减少显著相关。将药物使用量维持在临界阈值以下，与低水平的耐大环内酯类肺炎链球菌以及具有低适应成本的 erm(A) 携带 emm77 型肺炎链球菌数量增加有关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f33b/3437719/041cb00207b9/12-0049-F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f33b/3437719/334d6da5b4d7/12-0049-F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f33b/3437719/041cb00207b9/12-0049-F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f33b/3437719/334d6da5b4d7/12-0049-F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f33b/3437719/041cb00207b9/12-0049-F2.jpg

相似文献

1
Antimicrobial drug use and macrolide-resistant Streptococcus pyogenes, Belgium.抗微生物药物使用与耐大环内酯肺炎链球菌，比利时。
Emerg Infect Dis. 2012 Sep;18(9):1515-8. doi: 10.3201/eid1809.120049.
2
Unusual resistance patterns in macrolide-resistant Streptococcus pyogenes harbouring erm(A).携带erm(A)的耐大环内酯类化脓性链球菌中的异常耐药模式
J Antimicrob Chemother. 2009 Jan;63(1):42-6. doi: 10.1093/jac/dkn432. Epub 2008 Oct 24.
3
Differences in the DNA sequences in the upstream attenuator region of erm(A) in clinical isolates of Streptococcus pyogenes and their correlation with macrolide/lincosamide resistance.化脓性链球菌临床分离株中erm(A)上游衰减子区域的DNA序列差异及其与大环内酯类/林可酰胺类耐药性的相关性。
Antimicrob Agents Chemother. 2005 Jul;49(7):3070-2. doi: 10.1128/AAC.49.7.3070-3072.2005.
4
Plasmid-Borne erm(T) from invasive, macrolide-resistant Streptococcus pyogenes strains.侵袭性、耐大环内酯类化脓性链球菌菌株中质粒携带的erm(T)
Antimicrob Agents Chemother. 2008 Mar;52(3):1140-3. doi: 10.1128/AAC.01352-07. Epub 2008 Jan 7.
5
mef(A) is the predominant macrolide resistance determinant in Streptococcus pneumoniae and Streptococcus pyogenes in Germany.mef(A) 是德国肺炎链球菌和化脓性链球菌中主要的大环内酯类耐药决定因素。
Int J Antimicrob Agents. 2011 May;37(5):425-31. doi: 10.1016/j.ijantimicag.2011.01.019. Epub 2011 Mar 21.
6
Emergence of macrolide-resistant Streptococcus pyogenes strains in French children.法国儿童中耐大环内酯类化脓性链球菌菌株的出现。
Antimicrob Agents Chemother. 2004 Sep;48(9):3559-62. doi: 10.1128/AAC.48.9.3559-3562.2004.
7
Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study.从1999 - 2000年PROTEKT研究中分离出的肺炎链球菌和化脓性链球菌大环内酯类耐药机制的分子特征
J Antimicrob Chemother. 2002 Sep;50 Suppl S1:39-47. doi: 10.1093/jac/dkf806.
8
Detection of multiple macrolide- and lincosamide-resistant strains of Streptococcus pyogenes from patients in the Boston area.从波士顿地区患者中检测出多种对大环内酯类和林可酰胺类耐药的化脓性链球菌菌株。
J Clin Microbiol. 2004 Apr;42(4):1559-63. doi: 10.1128/JCM.42.4.1559-1563.2004.
9
Distribution of macrolide resistance mechanisms in Bulgarian clinical isolates of Streptococcus pyogenes during the years of 2013-2016.2013-2016 年保加利亚临床分离的酿脓链球菌中大环内酯类耐药机制的分布。
J Glob Antimicrob Resist. 2017 Sep;10:238-242. doi: 10.1016/j.jgar.2017.05.026. Epub 2017 Jul 19.
10
Macrolide and tetracycline resistance and emm type distribution of Streptococcus pyogenes isolates recovered from Turkish patients.从土耳其患者中分离出的酿脓链球菌对大环内酯类和四环素类的耐药性及 emm 型分布情况。
Microb Drug Resist. 2010 Dec;16(4):279-84. doi: 10.1089/mdr.2010.0021. Epub 2010 Jul 12.

引用本文的文献

1
An increase in erythromycin resistance in methicillin-susceptible from blood correlates with the use of macrolide/lincosamide/streptogramin antibiotics. EARS-Net Spain (2004-2020).甲氧西林敏感菌中红霉素耐药性的增加与大环内酯类/林可酰胺类/链阳菌素类抗生素的使用有关。西班牙抗菌药物耐药性监测网络（2004 - 2020年）。
Front Microbiol. 2023 Sep 26;14:1220286. doi: 10.3389/fmicb.2023.1220286. eCollection 2023.
2
Consumption of macrolides, lincosamides and streptogramins in the community, European Union/European Economic Area, 1997-2017.社区大环内酯类、林可酰胺类和链阳菌素类药物的消费情况，1997-2017 年，欧盟/欧洲经济区。
J Antimicrob Chemother. 2021 Jul 26;76(12 Suppl 2):ii30-ii36. doi: 10.1093/jac/dkab175.
3

本文引用的文献

1
European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe (1997-2009).欧洲抗菌药物监测系统（ESAC）：欧洲地区（1997-2009 年）的门诊抗生素使用情况。
J Antimicrob Chemother. 2011 Dec;66 Suppl 6:vi3-12. doi: 10.1093/jac/dkr453.
2
Inducible expression eliminates the fitness cost of vancomycin resistance in enterococci.诱导表达消除了肠球菌万古霉素耐药性的适应性代价。
Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16964-9. doi: 10.1073/pnas.1006855107. Epub 2010 Sep 10.
3
Antibiotic resistance and its cost: is it possible to reverse resistance?
emm Types and clusters and macrolide resistance of pediatric group A streptococcal isolates in Central Greece during 2011-2017.
2011-2017 年希腊中部地区儿科 A 组链球菌分离株的类型、聚类和大环内酯类耐药性。
PLoS One. 2020 May 7;15(5):e0232777. doi: 10.1371/journal.pone.0232777. eCollection 2020.
4
Antibiotic Resistance in Streptococcus pneumoniae after Azithromycin Distribution for Trachoma.阿奇霉素用于沙眼防治后肺炎链球菌的抗生素耐药性
J Trop Med. 2015;2015:917370. doi: 10.1155/2015/917370. Epub 2015 Oct 18.
5
Decline in macrolide resistance rates among Streptococcus pyogenes causing pharyngitis in children isolated in Italy.在意大利分离出的引起儿童咽炎的化脓性链球菌中，大环内酯类耐药率下降。
Eur J Clin Microbiol Infect Dis. 2015 Sep;34(9):1797-802. doi: 10.1007/s10096-015-2414-x. Epub 2015 May 30.
6
An in vitro deletion in ribE encoding lumazine synthase contributes to nitrofurantoin resistance in Escherichia coli.编码核黄素合酶的ribE基因中的体外缺失导致大肠杆菌对呋喃妥因耐药。
Antimicrob Agents Chemother. 2014 Dec;58(12):7225-33. doi: 10.1128/AAC.03952-14. Epub 2014 Sep 22.
7
A model-guided analysis and perspective on the evolution and epidemiology of antibiotic resistance and its future.对抗生素耐药性的演变、流行病学及其未来的模型引导分析与展望
Curr Opin Microbiol. 2014 Jun;19:83-89. doi: 10.1016/j.mib.2014.06.004. Epub 2014 Jul 11.
8
Epidemiology and molecular characterization of macrolide-resistant Streptococcus pyogenes in Taiwan.台湾地区大环内酯类耐药酿脓链球菌的流行病学和分子特征。
J Clin Microbiol. 2014 Feb;52(2):508-16. doi: 10.1128/JCM.02383-13. Epub 2013 Dec 4.
9
Seven-year surveillance of emm types of pediatric Group A streptococcal pharyngitis isolates in Western Greece.希腊西部儿科 A 组链球菌咽炎分离株 emm 型的 7 年监测。
PLoS One. 2013 Aug 19;8(8):e71558. doi: 10.1371/journal.pone.0071558. eCollection 2013.
抗生素耐药性及其代价：逆转耐药性是否可行？
Nat Rev Microbiol. 2010 Apr;8(4):260-71. doi: 10.1038/nrmicro2319. Epub 2010 Mar 8.
4
Achievements of the Belgian Antibiotic Policy Coordination Committee (BAPCOC).比利时抗生素政策协调委员会（BAPCOC）的成就。
Euro Surveill. 2008 Nov 13;13(46):19036.
5
Unusual resistance patterns in macrolide-resistant Streptococcus pyogenes harbouring erm(A).携带erm(A)的耐大环内酯类化脓性链球菌中的异常耐药模式
J Antimicrob Chemother. 2009 Jan;63(1):42-6. doi: 10.1093/jac/dkn432. Epub 2008 Oct 24.
6
Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study.阿奇霉素和克拉霉素治疗对健康志愿者咽部大环内酯类耐药链球菌携带情况的影响：一项随机、双盲、安慰剂对照研究。
Lancet. 2007 Feb 10;369(9560):482-90. doi: 10.1016/S0140-6736(07)60235-9.
7
Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.肺炎链球菌中氟喹诺酮耐药性的适合度代价
Antimicrob Agents Chemother. 2007 Feb;51(2):412-6. doi: 10.1128/AAC.01161-06. Epub 2006 Nov 20.
8
Macrolide resistance rates in respiratory pathogens in Slovenia following reduced macrolide use.斯洛文尼亚减少大环内酯类药物使用后呼吸道病原体中的大环内酯类耐药率
Int J Antimicrob Agents. 2006 Dec;28(6):537-42. doi: 10.1016/j.ijantimicag.2006.07.023. Epub 2006 Nov 13.
9
Macrolide-resistant Streptococcus pyogenes in Norway: population structure and resistance determinants.挪威耐大环内酯类化脓性链球菌：群体结构与耐药决定因素
Antimicrob Agents Chemother. 2006 May;50(5):1896-9. doi: 10.1128/AAC.50.5.1896-1899.2006.
10
Macrolide- and telithromycin-resistant Streptococcus pyogenes, Belgium, 1999-2003.1999年至2003年比利时对大环内酯类和泰利霉素耐药的化脓性链球菌
Emerg Infect Dis. 2005 Jun;11(6):939-42. doi: 10.3201/eid1106.041247.